Biomedicines 2014, 2(1), 110-131; doi:10.3390/biomedicines2010110
Review

Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy

Received: 20 December 2013; in revised form: 25 February 2014 / Accepted: 26 February 2014 / Published: 10 March 2014
(This article belongs to the Special Issue Gene Therapy Used in Cancer Treatment)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Adenoviruses (Ads) infect a broad range of tissue types, and derived vectors have been extensively used for gene therapy. Helper-dependent Ad vectors (HDAds), devoid of viral coding sequences, allow for insertion of large or multiple transgenes in a single vector and have been preclinically used for the study of genetic disorders. However, the clinical application of Ad vectors including HDAds for genetic disorders has been hampered by an acute toxic response. This characteristic, while disadvantageous for gene replacement therapy, could be strategically advantageous for the activation of an immune response if HDAds were used as an adjunct treatment in cancer. Cancer treatments including immunotherapy are frequently limited by the inhibitory environment produced by both tumors and their stroma, each of which express numerous inhibitory molecules. Hence, multiple inhibitory mechanisms must be overcome for development of anti-tumor immunity. The large coding capacity of HDAds can accommodate multiple immune modulating transgenes that could produce a combined effect to overcome tumor-derived inhibition and ensure intratumoral effector T-cell proliferation and function. In this review, we discuss the potential advantages of HDAds to cancer immunotherapy based on potent host immune responses to Ads.
Keywords: Helper-dependent adenoviral vector; immune response; pattern-recognition receptor; cancer immunotherapy
PDF Full-text Download PDF Full-Text [742 KB, Updated Version, uploaded 12 March 2014 12:05 CET]
The original version is still available [742 KB, uploaded 10 March 2014 11:48 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Farzad, L.M.; Suzuki, M. Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy. Biomedicines 2014, 2, 110-131.

AMA Style

Farzad LM, Suzuki M. Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy. Biomedicines. 2014; 2(1):110-131.

Chicago/Turabian Style

Farzad, Lisa M.; Suzuki, Masataka. 2014. "Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy." Biomedicines 2, no. 1: 110-131.

Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert